Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1505 of 5804
-
New putty could replace painful bone grafts for kids with cleft palate
Disease control CompletedIn this study, patients with unilateral cleft lip and palate are enrolled in a multicenter stepped wedge randomized trial ithat compares alveolar cleft closure using autologous bone harvested form the mandibular symphysis with an osteoinductive biphasic calcium phosphate putty.
Phase: NA • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug ORIC-944 targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThe purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
Phase: PHASE1 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Extra stitches may cut leak risk after rectal cancer surgery
Disease control ENROLLING_BY_INVITATIONStudy Description This prospective, controlled clinical study aims to compare the clinical outcomes of reinforced anastomosis using 8-10 interrupted sutures versus the conventional Dixon procedure in patients undergoing laparoscopic low anterior resection for low rectal cancer. A…
Phase: NA • Sponsor: Shanghai 10th People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New therapy aims to break the fear cycle after concussion
Symptom relief OngoingConcussions are very common. Although many people recover well from concussion, some will have persistent symptoms and difficulties with daily activities. How people cope with their symptoms following concussion powerfully influences their recovery. Fear avoidance behaviour is a …
Phase: NA • Sponsor: University of British Columbia • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
New hope for brain tumor patients: drug trial targets recurrent meningioma
Disease control Recruiting nowA Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Gut feeling: probiotic shows promise in curbing alcohol cravings and liver damage
Disease control Recruiting nowTo test the efficacy of 6-month LGG compared to placebo in treating Alcoholic Use Disorder (AUD) and liver injury in Alcoholic Hepatitis (AH). And to evaluate the effects of LGG treatment compared to placebo on therapeutic-mechanistic markers of the gut-brain axis and pro-inflamm…
Phase: PHASE2 • Sponsor: University of Louisville • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Could a single ketamine infusion ease daily headaches for months?
Symptom relief Recruiting nowChronic daily headaches (CDH) poses a significant burden on patients, healthcare systems and the society. Intravenous (IV) ketamine infusion, an intervention that is widely available and scalable, can treat CDH by reversing receptor-mediated sensitization. This study is a multice…
Phase: PHASE3 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can a supplement help balance hormones in PCOS?
Disease control CompletedThe purpose of the study is to understand the effect of Nicotinamide mononucleotide (NMN) on patients with polycystic ovary syndrome.
Phase: NA • Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Gut bacteria may help tame alcohol cravings, new study suggests
Disease control CompletedThis two-armed, parallel-group, double-blind, multi-center randomized control trial (RCT) aims to evaluate the efficacy of probiotic supplement compared with placebo in ameliorating alcohol craving and severity of alcohol use disorder (AUD) in patients diagnosed with AUD after 2 …
Phase: NA • Sponsor: Universiti Sains Malaysia • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat cancers
Disease control OngoingTo confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small c…
Phase: PHASE2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
Radiation after CAR-T: a new hope for myeloma patients?
Disease control Recruiting nowThis study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM. The study population will consist of subjects with RRMM previously treated with SOC BCMA CAR-T cell therapy with active …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental cell therapy aims to boost immune attack on breast cancer
Disease control TerminatedThe purpose of this study is to test the safety of Adoptive T-Cell therapy following the Dendritic Cell (DC1) study vaccine given in combination with pepinemab added to standard of care therapy, trastuzumab to help people with HER2 positive breast cancer.
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowEvaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New pill shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis is a phase II, open label, multicenter study of AZD4205 administered orally in participants with r/r PTCL to determine its safety, tolerability, PK, and anti-tumor activity. Eligible participants are those who had pathologically confirmed PTCL and have relapsed after or been…
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could a mitochondrial booster calm ulcerative colitis without heavy immune drugs?
Disease control OngoingThis is a Phase 2b, multi-centered, randomized, placebo-controlled trial with treatment phase over 24 weeks. Ulcerative Colitis (UC) is a condition that causes inflammation and ulceration of the inner lining of the rectum and colon (the large bowel). In UC, ulcers develop on the…
Phase: PHASE2 • Sponsor: University of Edinburgh • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThe primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011 with or without pembrolizumab. The primary objective of Parts B and C is to evaluate the an…
Phase: PHASE1, PHASE2 • Sponsor: Shionogi • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug TAKHZYRO tracked for Long-Term safety in rare swelling disorder
Disease control OngoingThis study is a survey in Japan of Lanadelumab used to treat people with hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main a…
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a single IV antibiotic dose send kids home sooner?
Disease control Recruiting nowUrinary tract infections (UTI) are commonly encountered in children, with 7% diagnosed with at least one UTI by the age of 19 years. The evidence for treatment of uncomplicated UTI is clear; oral antibiotics are as good as intravenous (IV) antibiotics, usually for a total of 7 da…
Phase: PHASE4 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug SHR-A1904 tested in patients with advanced cancers
Disease control Recruiting nowThe study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, …
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could argon gas help comatose cardiac arrest patients?
Disease control Recruiting nowPreclinical studies suggest that argon (Ar) might diminish the neurological and myocardial damage after any hypoxic-ischemic insult. Indeed, Ar has been tested in different models of ischemic insult, at concentrations ranging from 20% up to 80%. Overall, Ar emerged as a protectiv…
Phase: PHASE2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jun 26, 2026 18:00 UTC